Cargando…

High-dose intravenous methylprednisolone therapy in patients with Graves’ orbitopathy is associated with the increased activity of factor VIII

PURPOSE: Venous thromboembolic events (VTE), with their life-threatening manifestation as pulmonary embolism, are potential adverse effects of intravenous methylprednisolone (IVMP) pulse therapy, partially due to a hypercoagulable state. The aim of the study was to analyze the influence of IVMP on s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miśkiewicz, P., Milczarek-Banach, J., Rutkowska-Hinc, B., Kondracka, A., Bednarczuk, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394431/ https://www.ncbi.nlm.nih.gov/pubmed/29949121 http://dx.doi.org/10.1007/s40618-018-0907-z

Ejemplares similares

Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves’ Orbitopathy
por: Miskiewicz, Piotr, et al.
Publicado: (2018)

Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves' Orbitopathy
por: Miśkiewicz, Piotr, et al.
Publicado: (2018)

Therapy of moderate-to-severe Graves’ orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density
por: Rymuza, Joanna, et al.
Publicado: (2018)

Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy
por: Walasik-Szemplińska, Dorota, et al.
Publicado: (2019)

Decrease in Bone Formation and Bone Resorption during Intravenous Methylprednisolone Pulse Therapy in Patients with Graves’ Orbitopathy
por: Rymuza, Joanna, et al.
Publicado: (2022)

Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy
por: Eguchi, Hiroyuki, et al.
Publicado: (2015)

Clinical utility of TSH receptor antibody levels in Graves’ orbitopathy: a comparison of two TSH receptor antibody immunoassays
por: Bluszcz, Gabriela A., et al.
Publicado: (2018)

Treatment with Intravenous Methylprednisolone in Patients with Graves’ Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate
por: Pelewicz, Katarzyna, et al.
Publicado: (2020)

Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves’ Orbitopathy: A Pilot Study
por: Rymuza, Joanna, et al.
Publicado: (2022)

Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy
por: Bednarczuk, Tomasz, et al.
Publicado: (2019)

Is the treatment with pulses of methylprednisolone safe?
por: Bednarczuk, Tomasz, et al.
Publicado: (2013)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Efficacy and safety of low dose oral prednisolone as compared to pulse intravenous methylprednisolone in managing moderate severe Graves’ orbitopathy: A randomized controlled trial
por: Roy, Ajitesh, et al.
Publicado: (2015)

Bone turnover decreases and bone structure improves during treatment with weekly high-dose methylprednisolone for 12 weeks in Graves’ orbitopathy
por: Harsløf, Torben, et al.
Publicado: (2023)

Serum concentrations of HGF and IL-8 in patients with active Graves’ orbitopathy before and after methylprednisolone therapy
por: Nowak, M., et al.
Publicado: (2015)

Adipocytokines in Graves’ orbitopathy and the effect of high-dose corticosteroids
por: Schovanek, Jan, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Association between Polymorphisms in the TSHR Gene and Graves' Orbitopathy
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2014)

Recurrence of optic nerve neuropathy - a possible side effect of intravenous methylprednisolone pulses treatment
por: Trautsolt, Katarzyna, et al.
Publicado: (2013)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Network Meta-Analysis of Different Intravenous Glucocorticoid Regimes for the Treatment of Graves’ Orbitopathy
por: Jia, Jun, et al.
Publicado: (2022)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
por: Campi, Irene, et al.
Publicado: (2022)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Exposure to Bisphenol A Analogs and the Thyroid Function and Volume in Women of Reproductive Age—Cross-Sectional Study
por: Milczarek-Banach, Justyna, et al.
Publicado: (2021)

SAT-606 Graves' Orbitopathy Treated with Kahaly's Protocol: IV High Dose Glucocorticoids
por: Patel, Bijal, et al.
Publicado: (2019)

Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves' Orbitopathy
por: Lin, Miaoli, et al.
Publicado: (2015)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Clinical and imaging evaluation of the response to intravenous steroids in patients with Graves’ orbitopathy and analysis on who requires additional therapy
por: Tsirouki, Theodora, et al.
Publicado: (2016)

Editorial: Mechanisms and Novel Therapies in Graves’ Orbitopathy: Current Update
por: Zhou, Huifang, et al.
Publicado: (2022)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_44uiep1cgps36kudr2ikkd27cm